CELC (Celcuity) OCF Margin %: 0.00% (As of Mar. 2026)


CELC Celcuity Inc CELC
26 GF Score
Price $96.34
! 2 Warning Signs
View Full Analysis

What is Celcuity OCF Margin %?

Celcuity CELC +6.95% 26 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CELC with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Celcuity ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Celcuity's Cash Flow from Operations for the three months ended in Mar. 2026 was $-55.07 Mil. Celcuity's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Celcuity's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Celcuity's current OCF Yield % is -3.67%.

The historical rank and industry rank for Celcuity's OCF Margin % or its related term are showing as below:


CELC's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Celcuity OCF Margin % Related Terms

Celcuity OCF Margin % Historical Data

* Premium members only.

The historical data trend for Celcuity's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity OCF Margin % Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CELC
26GF Score
Celcuity Inc CELC
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Celcuity's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-153.28/0
= %

Celcuity's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-55.065/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Celcuity (CELC) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #999999 out of 959 companies in the Biotechnology industry.
Is Celcuity's OCF Margin % too high?
Celcuity's current OCF Margin % is 0.00%. Based on the distribution chart, Celcuity ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celcuity has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's OCF Margin % compare to PTGX and SYRE?
According to the Biotechnology industry distribution chart, Celcuity ranks #999999 out of 959 companies for OCF Margin %. This places Celcuity in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Celcuity and its competitors. Celcuity's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (CELC) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Celcuity's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Celcuity (CELC), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges 7VR:Germany
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
26GF Score

Get the complete analysis for CELC

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$96.34
Price